about
Maintaining Genome Stability in Defiance of Mitotic DNA DamageAurora kinases: novel therapy targets in cancersCharacterisation of CCT271850, a selective, oral and potent MPS1 inhibitor, used to directly measure in vivo MPS1 inhibition vs therapeutic efficacyIdentification of small molecule inhibitors of the Aurora-A/TPX2 complexA phase I study of BI 811283, an Aurora B kinase inhibitor, in patients with advanced solid tumors.Recombinant human bone morphogenetic protein-2 inhibits gastric cancer cell proliferation by inactivating Wnt signaling pathway via c-Myc with aurora kinases.Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer.Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma.Colorectal Cancer Cell Line Proteomes are Representative of Primary Tumors and Predict Drug Sensitivity.An update on the pharmacokinetics and pharmacodynamics of alisertib, a selective Aurora kinase A inhibitor.Cell Cycle Regulation and Melanoma.The functional role for condensin in the regulation of chromosomal organization during the cell cycle.Cell death response to anti-mitotic drug treatment in cell culture, mouse tumor model and the clinicA population pharmacokinetic model of AT9283 in adults and children to predict the maximum tolerated dose in children with leukaemia.Approved and Experimental Small-Molecule Oncology Kinase Inhibitor Drugs: A Mid-2016 Overview.Switching Aurora-A kinase on and off at an allosteric site.Structural propensities of kinase family proteins from a Potts model of residue co-variation.Chemical Genomics Approach Leads to the Identification of Hesperadin, an Aurora B Kinase Inhibitor, as a Broad-Spectrum Influenza Antiviral.APIO-EE-9 is a novel Aurora A and B antagonist that suppresses esophageal cancer growth in a PDX mouse model.Deguelin, an Aurora B Kinase Inhibitor, Exhibits Potent Anti-Tumor Effect in Human Esophageal Squamous Cell Carcinoma.Solid Cancer Treatment With Aurora Kinase Inhibitors: Towards a Personalized Medicine.Evolving Therapeutic Strategies to Exploit Chromosome Instability in Cancer.The therapeutic potential of cell cycle targeting in multiple myeloma.MIR21 drives resistance to Heat Shock Protein 90 inhibition in cholangiocarcinoma.Target Identification of Kinase Inhibitor Alisertib (MLN8237) by Using DNA-Programmed Affinity Labeling.RIPK1-dependent cell death: a novel target of the Aurora kinase inhibitor Tozasertib (VX-680).Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia.Protein Complexes in the Nucleus: The Control of Chromosome Segregation.Targeting DNA damage repair in small cell lung cancer and the biomarker landscape.HIPK2 and extrachromosomal histone H2B are separately recruited by Aurora-B for cytokinesis.Head-to-head comparison of the impact of Aurora A, Aurora B, Repp86, CDK1, CDK2 and Ki67 expression in two of the most relevant gynaecological tumor entities.Synthesis and profiling of a 3-aminopyridin-2-one-based kinase targeted fragment library: Identification of 3-amino-5-(pyridin-4-yl)pyridin-2(1H)-one scaffold for monopolar spindle 1 (MPS1) and Aurora kinases inhibition.The multifaceted allosteric regulation of Aurora kinase A.Dynamics of human protein kinase Aurora A linked to drug selectivityAurora kinase A localises to mitochondria to control organelle dynamics and energy production
P2860
Q26738970-72E204F6-1ABD-4FB5-ADB6-27AB2C7EF12FQ33618929-8CEAAC4C-4183-4071-B844-12B8D36CCA0BQ33639719-DB88F5ED-9886-41ED-A367-C321E29C935EQ33762037-9F3ECA5D-C77A-4AD7-8DE1-E634D3E2DEADQ37366202-BA1471EC-8001-4681-8F6D-99670E02A037Q37687413-F23F2F32-DB00-4BEA-9DA1-59DA81BE7A8DQ38694488-4AE2B26B-6226-4647-9D07-BAA2369A1C56Q38695950-4190C46F-4E0B-46C2-B689-0F2C74C40EBCQ38699958-FE988710-B1F4-40F0-8C5D-BFBEC81D3DEBQ38783162-ACAE5F69-58E1-4B98-B2BC-A7106548965BQ38815527-30AEA121-A1BA-4AA4-A953-CF032797A9A1Q38893228-D8482253-C629-478B-91E6-5DDDFF4F121BQ38935027-8222AB6B-ADB8-46F2-AEE7-34361170260CQ38972542-8D852970-DD5F-4AA5-82A0-C78AE15918DFQ38989374-D444662B-3277-42ED-A3B6-0548EEE35212Q39200217-320C3A90-3C93-4CA9-A821-ABAC41DEF04FQ39724623-1FEEFF13-7264-43AC-94FE-932B6D5A3A5FQ40051127-54ED20DF-612F-4D9C-8A49-B2F08DF7B50EQ41593187-7D94A2C6-8268-4A64-B4D1-05F85021ABD5Q45874344-FA1A2A4D-942A-464E-9551-5E4368B31876Q47111493-4BF9B52C-7DD5-4304-B3AE-B833848E499EQ47119995-5A873AED-FAAD-42B6-AAC6-A589318D2BDCQ47203904-301738C1-0425-4087-9400-CE57965329FEQ47429093-35648D5D-8584-4AFC-9191-518627B831B3Q48307732-70F2A355-A773-4FD4-BA93-810C93BB8991Q49025576-0793A43A-483B-458E-A5AE-141F0AF0323AQ49887884-C7D4BB7C-FB96-487C-97D1-E142E7A1D893Q50856198-0F3F9FF3-FA3F-4A30-B338-8F4C6546B214Q52657032-B23CEB10-30F6-415C-818F-420FD07D9B23Q52725117-C8FBC1A5-F62E-40C6-B543-8DFB8720ABDBQ53203084-D2266704-2167-4B73-881F-22F3C4929593Q54109642-9185C9BB-0E64-4E96-9214-2C30ACCDE03CQ55486788-13952BB5-6AD8-4E94-9280-2FE17B7C7D31Q56889888-58B739B1-3722-4365-AA93-5910EAC06E0FQ58802722-F5BD6B5E-0C1C-4152-AB81-E5B864C719AA
P2860
description
2015 nî lūn-bûn
@nan
2015 թուականին հրատարակուած գիտական յօդուած
@hyw
2015 թվականին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Aurora Kinase Inhibitors: Current Status and Outlook
@ast
Aurora Kinase Inhibitors: Current Status and Outlook
@en
Aurora Kinase Inhibitors: Current Status and Outlook
@nl
type
label
Aurora Kinase Inhibitors: Current Status and Outlook
@ast
Aurora Kinase Inhibitors: Current Status and Outlook
@en
Aurora Kinase Inhibitors: Current Status and Outlook
@nl
prefLabel
Aurora Kinase Inhibitors: Current Status and Outlook
@ast
Aurora Kinase Inhibitors: Current Status and Outlook
@en
Aurora Kinase Inhibitors: Current Status and Outlook
@nl
P2860
P3181
P356
P1476
Aurora Kinase Inhibitors: Current Status and Outlook
@en
P2093
Vassilios Bavetsias
P2860
P3181
P356
10.3389/FONC.2015.00278
P407
P577
2015-12-21T00:00:00Z